U.S. Markets close in 3 hrs 43 mins

Cytori Therapeutics, Inc. (CYTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.39-0.02 (-4.48%)
As of 12:16PM EDT. Market open.
People also watch

Cytori Therapeutics, Inc.

3020 Callan Road
San Diego, CA 92121
United States

Full Time Employees65

Key Executives

Dr. Marc H. Hedrick M.D.Pres, CEO & Director596.25kN/A54
Mr. Tiago M. GiraoVP of Fin., CFO & Principal Accounting Officer344.56kN/A38
Mr. John D. HarrisVP & GM of Cell Therapy551.44kN/A48
Dr. John K. Fraser Ph.D.Chief ScientistN/AN/A56
Mr. Jeremy B. HaydenChief Compliance Officer, VP of Bus. Devel., Gen. Counsel and Sec.N/AN/A47
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The company also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s Sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer. It serves hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through direct sales force, third-party distributors, independent sales representatives, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California.

Corporate Governance

Cytori Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.